Natixis Roivant Sciences Ltd. Transaction History
Natixis
- $17.6 Billion
- Q3 2024
A detailed history of Natixis transactions in Roivant Sciences Ltd. stock. As of the latest transaction made, Natixis holds 68 shares of ROIV stock, worth $786. This represents 0.0% of its overall portfolio holdings.
Number of Shares
68Holding current value
$786% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding ROIV
# of Institutions
310Shares Held
507MCall Options Held
1.26MPut Options Held
2.52M-
Sb Investment Advisers (Uk) LTD London, X065.9MShares$763 Million6.27% of portfolio
-
Qvt Financial LP New York, NY65.8MShares$761 Million73.2% of portfolio
-
Viking Global Investors LP54.1MShares$626 Million2.42% of portfolio
-
Vanguard Group Inc Valley Forge, PA41.7MShares$482 Million0.01% of portfolio
-
Black Rock Inc. New York, NY35.4MShares$409 Million0.01% of portfolio
About Roivant Sciences Ltd.
- Ticker ROIV
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 704,382,976
- Market Cap $8.15B
- Description
- Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne...